Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrices and benchmarks.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 27 10 2021
accepted: 21 06 2022
entrez: 18 7 2022
pubmed: 19 7 2022
medline: 22 7 2022
Statut: epublish

Résumé

The Joint United Nations Programme on AIDS (UNAIDS) has emphasized on the incidence-prevalence ratio (IPR) and incidence-mortality ratio (IMR) to measure the progress in HIV epidemic control. In this paper, we describe the status of epidemic control in India and in various states in terms of UNAIDS's recommended metrices. The National AIDS Control Programme (NACP) of India spearheads work on mathematical modelling to estimate HIV burden based on periodically conducted sentinel surveillance for providing guidance to program implementation and policymaking. Using the results of the latest round of HIV Estimations in 2019, IPR and IMR were calculated. National level IPR was 0.029 [0.022-0.037] in 2019 and ranged from 0.01 to 0.15 in various States and Union Territories (UTs). Corresponding Incidence-Mortality Ratio was at 0.881 [0.754-1.014] nationally and ranged between 0.20 and 12.90 across the States/UTs. Based on UNAIDS recommended indicators for HIV epidemic control, namely IPR and IMR; national AIDS response in India appears on track. However, the program success is not uniform and significant heterogeneity as well as expanding epidemic was observed at the level of States or UTs. Reinforcing States/UTs specific and focused HIV prevention, testing and treatment initiatives may help in the attainment of 2030 Sustainable Development Goals of ending AIDS as a public health threat by 2030.

Sections du résumé

BACKGROUND
The Joint United Nations Programme on AIDS (UNAIDS) has emphasized on the incidence-prevalence ratio (IPR) and incidence-mortality ratio (IMR) to measure the progress in HIV epidemic control. In this paper, we describe the status of epidemic control in India and in various states in terms of UNAIDS's recommended metrices.
METHOD
The National AIDS Control Programme (NACP) of India spearheads work on mathematical modelling to estimate HIV burden based on periodically conducted sentinel surveillance for providing guidance to program implementation and policymaking. Using the results of the latest round of HIV Estimations in 2019, IPR and IMR were calculated.
RESULTS
National level IPR was 0.029 [0.022-0.037] in 2019 and ranged from 0.01 to 0.15 in various States and Union Territories (UTs). Corresponding Incidence-Mortality Ratio was at 0.881 [0.754-1.014] nationally and ranged between 0.20 and 12.90 across the States/UTs.
CONCLUSIONS
Based on UNAIDS recommended indicators for HIV epidemic control, namely IPR and IMR; national AIDS response in India appears on track. However, the program success is not uniform and significant heterogeneity as well as expanding epidemic was observed at the level of States or UTs. Reinforcing States/UTs specific and focused HIV prevention, testing and treatment initiatives may help in the attainment of 2030 Sustainable Development Goals of ending AIDS as a public health threat by 2030.

Identifiants

pubmed: 35849570
doi: 10.1371/journal.pone.0270886
pii: PONE-D-21-34403
pmc: PMC9292090
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0270886

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
AIDS. 2019 Dec 15;33 Suppl 3:S227-S234
pubmed: 31805028
Int J Epidemiol. 2020 Apr 1;49(2):666-675
pubmed: 31930292
J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):89-92
pubmed: 14707798
Indian J Med Res. 2020 Jun;151(6):562-570
pubmed: 32719229
Sex Transm Infect. 2012 Jun;88(4):240-9
pubmed: 22510332
Indian J Community Med. 2012 Apr;37(2):83-8
pubmed: 22654280
PLoS Med. 2018 Oct 25;15(10):e1002678
pubmed: 30359372
Indian J Public Health. 2020 Apr;64(Supplement):S4-S7
pubmed: 32295949
AIDS. 2019 Dec 15;33 Suppl 3:S203-S211
pubmed: 31343430
Medicine (Baltimore). 2021 Jul 16;100(28):e26578
pubmed: 34260537
Lancet HIV. 2018 Nov;5(11):e667-e670
pubmed: 30314745
Indian J Public Health. 2020 Apr;64(Supplement):S76-S78
pubmed: 32295961
PLoS Med. 2019 Jan 18;16(1):e1002729
pubmed: 30657770
Sex Transm Infect. 2012 Dec;88 Suppl 2:i11-6
pubmed: 23172341
AIDS. 2006 Sep 11;20(14):1898-901
pubmed: 16954735
Epidemiol Infect. 2004 Dec;132(6):1139-49
pubmed: 15635973
PLoS Med. 2021 Oct 18;18(10):e1003831
pubmed: 34662333

Auteurs

Pradeep Kumar (P)

National AIDS Control Organization, Ministry of Health and Family Welfare, New Delhi, India.

Chinmoyee Das (C)

National AIDS Control Organization, Ministry of Health and Family Welfare, New Delhi, India.

Arvind Kumar (A)

National AIDS Control Organization, Ministry of Health and Family Welfare, New Delhi, India.

Damodar Sahu (D)

Indian Council of Medical Research-National Institute of Medical Statistics, New Delhi, India.

Sanjay K Rai (SK)

All India Institute of Medical Sciences, New Delhi, India.

Sheela Godbole (S)

Indian Council of Medical Research-National AIDS Research Institute, Pune, India.

Elangovan Arumugam (E)

Indian Council of Medical Research-National Institute of Epidemiology, Chennai, India.

Lakshmi P V M (L)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Shanta Dutta (S)

Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases, Kolkata, India.

H Sanayaima Devi (HS)

Regional Institute of Medical Sciences, Imphal, India.

Vishnu Vardhana Rao Mendu (V)

Indian Council of Medical Research-National Institute of Medical Statistics, New Delhi, India.

Shashi Kant (S)

All India Institute of Medical Sciences, New Delhi, India.

Arvind Pandey (A)

Indian Council of Medical Research-National Institute of Medical Statistics, New Delhi, India.
Indian Council of Medical Research, New Delhi, India.

Dandu Chandra Sekhar Reddy (DCS)

Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

Sanjay Mehendale (S)

Indian Council of Medical Research, New Delhi, India.
PD Hinduja Hospital and Medical Research Center, Mumbai, India.

Shobini Rajan (S)

National AIDS Control Organization, Ministry of Health and Family Welfare, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH